In combination with GLP-1, GIP appears to amplify the brains recognition of fullness, further reducing food intake
This dual action, promoting the breakdown of existing fat while simultaneously slowing the creation of new fat, makes the theoretical mechanism appealing
The table below outlines this general pattern in broad terms, without providing specific instructions for self-administration
Cell Rep Med 2022;3:100813.ArticlePubMedPMC 93
Fatigue is a recognised adverse reaction in the product information for some GLP-1 medications, particularly those used at higher doses for weight management (such as semaglutide 2.4 mg and liraglutide 3 mg)
For the injectable GLP-1 RAs, this shouldnt be much of an issue, as the companys dosing aligns nicely with the research